Charles Kent LtdePortfolio

Charles Kent LtdVisual Communications Specialist

Diagrams

Before…

…After

ANP

Hypertrophic gene program

Ca2+

Ca2+

Calcineurin

NFAT

NFATGATA

CaMKIIcGMP

GTP

PKGRGS2

Angiotensin II

TRPC 3/6 GPCR

GC-A

TRRC

MCP

IP3

NFAT

P

P

PLC

RGS2

Goq

GTP

Before…Pre-launch Launch Post-Launch

Online resource for oncologists

and pathologists a therapy area

portal approach

Brand website

New MOA for EGFR-TKI

Plugging into the established

communication networks

Congress activities

EGFR testing app

Augmented reality/ interactive sales aids

Patient portal

Materials produced in conjunction with patient organisations

Multichannel integration: Our approach is to ensure activities are integrated into the communication strategy to enable maximum reach with key stakeholders with consistent messaging across all channels

Booth materials

After…PRE-LAUNCH LAUNCH POST-LAUNCH

Congress activities

Plugging into the established

communication networks

Patient portal

Online resource for oncologists and pathologists a therapy area

portal approach

New MOA for EGFR-TKI

Materials produced in conjunction with patient

organisationsBooth materials

Augmented reality/ interactive sales aids

Brand website

EGFR testing app

> Multichannel integration: Our approach is to ensure activities are integrated into the communication strategy to enable maximum reach with key stakeholders with consistent messaging across all channels

Before…

Induction +28–42d post cycle 4, Maintenance 25m post

cycle 4

Product A 375 mg/m2 IV

Product A 375 mg/m2 IV

• Relapsed CD20+ iNHL

• Prior response >6 mo to last

Product A rx

ABC101 ( Product B ) 1000 mg IV

ABC101 ( Product B ) 1000 mg IV

9 PD Discontinue

Treatment

CT/PET “

CT/PET “

CT CT CT CT “ “ “ “ 3m 6m 12m 18m

CT “

25m

Randomized phase II trial comparing ABC101 (Product B) with product A in patients with relapsed CD20+ indolent B-cell NHL

w1 w2 w3 w4 m2 m4 m6 m24 ………

RA

ND

OM

IZA

TIO

N

En

d o

f In

du

cti

on

En

d o

f M

ain

ten

an

ce

After…

• Relapsed CD20+ iNHL

• Prior response 6 mo to last product A rx

Induction Maintenance

Product A375 mg/m2 IV

Product A375 mg/m2 IV

ABC101(Product B)1000 mg IV

ABC101(Product B) 1000 mg IV

End ofinduction

End ofmaintenance

+28–42d post cycle 4

25m post cycle 4

CT/PET

Randomization

CT CT CT CT CTCT/PET

3m 6m 12m 18m 25m

PD discontinue treatment

Randomized phase II trial comparing ABC101 (Product B) with product A in patients with relapsed CD20+ indolent B-cell NHL

w1 w2 w3 w4 m2 m4 m6 m24

Before…

After…

Standardised measures to track/quantify symptoms

(eg ACT, ASQ, CAT)

Peak flow diary results, spirometry results/pulmonary

function tests (FEV1)

If patient presents to HCP (outside of a routine consultation) this is first indicator

that they may not be ‘controlled’

Basic questions about symptoms experienced and exposure to triggers

(many have a battery of questions they use)

Symptomquantification

Objectiveclinical

measures

Symptom report /questioning

Patient presentation

ACT and ASQ are useful but we don’t go through each of them,

just pick specific questions.SPECIALIST, Dublin

Ultimately it is a clinical syndrome so we are looking at that rather than lab measures to monitor.

SPECIALIST, Dublin

If they are notseeing us we hopethey are controlled.

NURSE, Manchester

Lessused

Layout

Figure Redrawing for Posters,Presentations & Manuscripts

Before…

After…LV

ED

V (

ml)

0

100

200

300

LVE

SV

(m

l)

0

100

200

SV

(m

l)

0

40

60

80

20

*

EF

(%

)

0

20

40

60

TP

R

(dyn

e-s

ec-

cm–5

)

0

2000

3000

AN

F (

pg

/ml)

0

40

60

20

* *

* *

**

* ** *

*

**

1000

* *

Controls CHF Controls CHF

Base 60’ 120’ Base 60’ 120’ Base 60’ 120’ Base 60’ 120’Time (minutes) Time (minutes)

**

* *

* *

**

* *

**

**

**

Before…Comparator 1 – Overall Survival

Prior Platinum Exposure

HR 1.23 (95% CI 0.45-6.78)RR: 12% (CP) vs 34% (TP)

HR 1.23 (95% CI 0.45-6.78)RR: 12% (CP) vs 34% (TP)

Prior Comparator A No Prior Comparator A

Comparator A backbone

Comparator A backbone

Comparator B backboneComparator B backbone

After…

Comparator 1 – Overall Survival Prior Platinum Exposure`

Pro

port

ion

surv

ivin

g

Months on Study

0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0.9

1.0

0 2412 186

Prior Comparator A No Prior Comparator A

Pro

port

ion

surv

ivin

g

Months on Study

0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0.9

1.0

0 2412 186

HR: 1.23 (95% CI 0.45–6.78)RR: 12% (CP) vs 34% (TP)

HR: 1.23 (95% CI 0.45–6.78)RR: 12% (CP) vs 34% (TP)

Comparator A

Comparator B

Alive 123 45Dead 67 89Total 112 345

Comparator A

Comparator B

Alive 123 45Dead 67 89Total 112 345

Before…

After…S

V (

ml)

0

50

100

AN

F (

pg/m

l)

0

60

20

180 280 180 280

Untreated CEIBase60’

120’Volume Expansion

Before…

After…

Software Applications

Advanced User:

Adobe Illustrator CC

Adobe Photoshop CC

Adobe InDesign CC

Adobe Acrobat

Microsoft Powerpoint (2013)

Microsoft Word (2013)

Microsoft Excel (2013)

Quark Express